Drug therapy for ventricular tachyarrhythmia in heart failure

Circulation Journal

Volumn 71, Issue SUPPL. A, 2007, Pages

  Shiga, Tsuyoshi ^a   Kasanuki, Hiroshi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Amiodarone; Beta blocker; Heart failure; Sudden cardiac death; Ventricular arrhythmia

Indexed keywords

ADRENALIN; ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARRIER PROTEIN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; ION CHANNEL; LIDOCAINE; LOOP DIURETIC AGENT; METOPROLOL; NIFEKALANT; PROCAINAMIDE; SOTALOL; SPIRONOLACTONE;

ANTIARRHYTHMIC ACTIVITY; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DEFIBRILLATION; DISEASE EXACERBATION; DRUG SAFETY; EMERGENCY TREATMENT; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LOW DRUG DOSE; PHARMACODYNAMICS; QT PROLONGATION; REVIEW; RISK REDUCTION; SUDDEN DEATH; SURVIVAL; THYROID FUNCTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-ARRHYTHMIA AGENTS; DEATH, SUDDEN, CARDIAC; HEART FAILURE; HUMANS; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 34347234492     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.A90     Document Type: Review

References (58)

1. Narang R, Cleland JG, Erhardt L, Ball SG, Coats AJ, Cowley AJ, et al. Mode of death in chronic heart failure: A request and proposition for more accurate classification. Eur Heart J 1996; 17: 1390-1403.
2. Bayes de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151-159.
3. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 1993; 73: 379-385.
4. Li GR, Lau CP, Ducharme A, Tardif JC, Nattel S. Transmural action potential and ionic current remodeling in ventricles of failing canine hearts. Am J Physiol Heart Circ Physiol 2002; 283: H1031-H1041.
5. Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 415: 198-205.
6. Piacentino VÖ, Weber CR, Chen X, Weisser-Thomas J, Marqulies KB, Bers DM, et al. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. Circ Res 2003; 92: 651-658.
7. Hoppe UC, Jansen E, Südkamp M, Beuckelmann DJ. Hyperpolarization- activated inward current in ventricular myocytes from normal and failing human hearts. Circulation 1998; 97: 55-65.
8. Kamkin A, Kiseleva I, Isenberg G. Stretch-activated currents in ventricular myocytes: Amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 2000; 48: 409-420.
9. Severs NJ, Dupont E, Thomas N, Koba R, Rothery S, Jain R, et al. Alterations in cardiac connexin expression in cardiomyopathies. Adv Cardiol 2006; 42: 228-242.
10. Rubart M, Zipes D. Mechanisms of sudden cardiac death. J Clin Invest 2005; 115: 2305-2315.
11. Singh BN. β-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: An overview. J Cardiovasc Pharmacol Ther 2005; 10(Suppl 1): S3-S14.
12. Adamson PB, Gilbert EM. Reducing the risk of sudden death in heart failure with β-blockers. J Card Fail 206; 12: 734-746.
13. Domanski MJ, Exner DV, Borkowf CB, Geller NL, Rosenberg Y, Pfeffer MA. Effect of angiotensin converting enzyme inhibition on sudden death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33: 598-604.
14. Cohn JN, Goldstein SO, Greengerg BH, Lorell BH, Bourge RC, Jaski BE, et al, for the Vesnarinone Trial Investigators. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998; 339: 1810-1816.
15. American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 7.2: Management of cardiac arrest. Circulation 2005; 112: IV-58-IV-66.
16. Kudenchuk P, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, et al. Amiodarone for resusucitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med 1999; 341: 871-878.
17. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med 2000; 346: 884-890.
18. Amino M, Yoshioka K, Iwata O, Fujikura H, Deguchi Y, Ban K, et al. Efficacy of nifekalant hydrochloride for life-threatening ventricular tachyarrhythmias in patients with resistance to lidocaine: A study of patients with out-of-hospital cardiac arrest. J Cardiol 2003; 41: 127-134 (in Japanese with English abstract).
19. Igarashi M, Toyoda M, Uno N, Nii H, Sasao K, Ozawa T, et al. Defibrillation effects of Nifekalant in patients with out-of-hospital ventricular fibrillation. Shinzo 2003; 35(Suppl 3): 99-103 (In Japanese).
20. Yoshioka K, Amino M, Morita S, Nakagawa Y, Usui K, Sugimoto A, et al. Can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest (CPA)?: Comparative study of out-of-hospital CPA with acidosis and in-hospital CPA without acidosis. Circ J 2006; 70: 21-27.
21. Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: Post-marketing special investigation. Circ J 2005; 69: 1237-1243.
22. Gorgels AP, van den Dool A, Hofs A, Mulleneers R, Sneets JL, Vos MA, et al. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia. Am J Cardiol 1996; 78: 82-83.
23. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993; 22: 61A-71A.
24. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002; 415: 206-212.
25. Barrington PL, Ten Eick RE. Characterization of the electrophysiological effects of metoprolol on isolated feline ventricular myocytes. J Pharmacol Exp Ther 1990; 252: 1043-1052.
26. 2+ current in rabbit ventricular myocytes. Eur J Pharmacol 1999; 376: 189-201.
27. Chen J, Kamiya K, Kodama I. Carvedilol: Molecular and cellular basis for its multifaced therapeutic potential. Cardiovasc Drug Rev 2001; 19: 152-171.
28. Karle CA, Kreye VA, Thomas D, Rockl K, Kathofer S, Zhang W, et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 2001; 49: 361-370.
29. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al, for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.
30. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
31. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002; 106: 2194-2199.
32. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380.
33. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-1773.
34. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.
35. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al, for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-1446.
36. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
37. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al, for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362: 7-13.
38. Torp-Pedersen C, Poole-Wilson PA, Swedberg K, Cleland JGF, DiLenarda A, Hanrath P, et al, for the COMET Investigators. Effects of metoprolol and carvedilol on cause-specific mortality in chronic heart failure patients: COMET. Am Heart J 2005; 149: 370-376.
39. McMurray J, Kober L, Robertson M, Dargie H, Colucci W, Lopz-Sendon J, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 2005; 45: 525-530.
40. Metra M, Torp-Pedersen C, Swedberg K, Cleland JGF, Di Lenarda A, Komajda M, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: Results from the COMET trial. Eur Heart J 2005; 26: 2259-2268.
41. Bristow MR, Larrabeee P, Minobe W, Roden R, Skerl L, Klein J, et al. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992; 19(Suppl 1): S68-S80.
42. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
43. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
44. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
45. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
46. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldactone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309.
47. Kodama I, Kamiya H, Toyama J. Amiodarone: Ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 1999; 84: 20R-28R.
48. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-412.
49. Amiodarone Trial Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomized trials. Lancet 1997; 350: 1417-1424.
50. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al, for the Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82.
51. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R, for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-498.
52. Ezekowitz JA, Armstrong PW, McAlister FA. Implantable Cardioverter Defibrillators in primary and secondary prevention: A systemic review of randomized, controlled trials. Ann Intern Med 2003; 138: 512-514.
53. Adam Strickberger A, Hummel JD, Bartlett TG, Frumin H, Schuger CD, Beau SL, et al, for the AMIOVIRT Investigators. Amiodarone versus implantable cardioverter-defibrillator: Randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia: AMIOVIRT. J Am Coll Cardiol 2003; 41: 1707-1712.
54. Boutitie F, Boissel JP, Connolly SJ, Camm AJ, Cairns JA, Julian DG, et al, and the EMIAT and CAMIAT Investigators. Amiodarone interaction with beta-blockers: Analysis of the Merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. Circulation 1999; 99: 2268-2275.
55. Connoly S, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al, for the Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: A randomized trial. JAMA 2006; 295: 165-171.
56. Mason JW, for the Electrophysiologic study versus Electrocardiographic Monitoring Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329: 452-458.
57. Waldo AL, Camm AJ, deRuytar H, Friedman PL, MacMeil DJ, Pauls JF, et al, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996; 348: 7-12.
58. Woosley RL, Barbey JT, Wang T, Funck-Brentano C. Concentration/response relations for the multiple antiarrhythmic actions of sotalol. Am J Cardiol 1990; 65: 22A-27A.